Cellular senescence mediates fibrotic pulmonary disease

Nature Communications

Volumn 8, Issue , 2017, Pages

  Schafer, Marissa J ^a   White, Thomas A ^a   Iijima, Koji ^a   Haak, Andrew J ^b   Ligresti, Giovanni ^b   Atkinson, Elizabeth J ^a   Oberg, Ann L ^a   Birch, Jodie ^c   Salmonowicz, Hanna ^c   Zhu, Yi ^a   Mazula, Daniel L ^a   Brooks, Robert W ^d   Fuhrmann Stroissnigg, Heike ^d   Pirtskhalava, Tamar ^a   Prakash, Y S ^a,b   Tchkonia, Tamara ^a   Robbins, Paul D ^d   Aubry, Marie Christine ^a   Passos, Joaõ F ^c   Kirkland, James L ^a,b   Tschumperlin, Daniel J ^b   Kita, Hirohito ^a   LeBrasseur, Nathan K ^a,b   more..

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; DASATINIB; PROTEIN P16; QUERCETIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEOME;

ABUNDANCE; BIOMARKER; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; DISEASE SEVERITY; GENE EXPRESSION; RESPIRATORY DISEASE; RODENT; SENESCENCE;

ANIMAL EXPERIMENT; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL AGING; CELL DIVISION; CELL KILLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EARLY INTERVENTION; EXPERIMENTAL LUNG INJURY; FIBROSING ALVEOLITIS; HEALTH; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG; LUNG FIBROBLAST; LUNG FUNCTION; LUNG PARENCHYMA; MOUSE; NONHUMAN; SUICIDE GENE; TRANSGENICS; ANIMAL; FIBROBLAST; MALE; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

MUS;

ANIMALS; BIOMARKERS; BLEOMYCIN; CELLULAR SENESCENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MICE; PROTEOME;

EID: 85013807598     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14532     Document Type: Article

References (49)

1. Wynn, T. A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339-1350 (2011).
2. Ashcroft, G. S., Horan, M. A., Ferguson, M. W. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. Lab. Invest. 78, 47-58 (1998).
3. Hecker, L., et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014).
4. King, T. E. Jr, Pardo, A., Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949-1961 (2011).
5. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161, 646-664 (2000).
6. Kim, E. S., Keating, G. M. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 75, 219-230 (2015).
7. Spagnolo, P., et al. Idiopathic pulmonary fibrosis: an update. Ann. Med. 47, 15-27 (2015).
8. van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439-446 (2014).
9. Demaria, M., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722-733 (2014).
10. Krizhanovsky, V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667 (2008).
11. Faner, R., Rojas, M., Macnee, W., Agusti, A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 186, 306-313 (2012).
12. Kuwano, K., et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 154, 477-483 (1996).
13. Lomas, N. J., Watts, K. L., Akram, K. M., Forsyth, N. R., Spiteri, M. A. Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers. Int. J. Clin. Exp. Pathol. 5, 58-71 (2012).
14. Yanai, H., et al. Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients. Aging (Albany NY) 7, 664-672 (2015).
15. Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., Breuer, R. Time course of bleomycin-induced lung fibrosis. Int. J. Exp. Pathol. 83, 111-119 (2002).
16. Aoshiba, K., Tsuji, T., Nagai, A. Bleomycin induces cellular senescence in alveolar epithelial cells. Eur. Respir. J. 22, 436-443 (2003).
17. Aoshiba, K., et al. Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. Exp. Toxicol. Pathol. 65, 1053-1062 (2013).
18. Li, Y., et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J. Exp. Med. 208, 1459-1471 (2011).
19. Li, Y., et al. Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis. Matrix Biol. 55, 35-48 (2016).
20. Hashimoto, M., et al. Elimination of p19ARF-expressing cells enhances pulmonary function in mice. JCI Insight 1, e87732 (2016).
21. Zhu, Y., et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428-435 (2015).
22. Zhu, Y., et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644-658 (2015).
23. Lim, H., Park, H., Kim, H. P. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts. Biochem. Pharmacol. 96, 337-348 (2015).
24. Calhoun, C., et al. Senescent cells contribute to the physiological remodeling of aged lungs. J. Gerontol. A Biol. Sci. Med. Sci. 71, 153-160 (2016).
25. Hewitt, G., et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat. Commun. 3, 708:2012
26. Winkler, M. K., Fowlkes, J. L. Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis? Am. J. Physiol. Lung Cell Mol. Physiol. 283, L1-11 (2002).
27. Boldt, H. B., Conover, C. A. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm. IGF Res. 17, 10-18 (2007).
28. Agassandian, M., et al. VCAM-1 is a TGF-beta1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal. 27, 2467-2473 (2015).
29. Desmouliere, A., Geinoz, A., Gabbiani, F., Gabbiani, G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122, 103-111 (1993).
30. Marinkovic, A., Mih, J. D., Park, J. A., Liu, F., Tschumperlin, D. J. Improved throughput traction microscopy reveals pivotal role for matrix stiffness in fibroblast contractility and TGF-beta responsiveness. Am. J. Physiol. Lung Cell Mol. Physiol. 303, L169-L180 (2012).
31. Baker, D. J., et al. Clearance of p16Ink4a-positive senescent cells delays ageingassociated disorders. Nature 479, 232-236 (2011).
32. Baker, D. J., et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184-189 (2016).
33. Roos, C. M., et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15, 973-977 (2016).
34. Xu, M., et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife 4, e12997 (2015).
35. Frazer, D. G., Reynolds, J. S., Jackson, M. C. Determining when enhanced pause (Penh) is sensitive to changes in specific airway resistance. J. Toxicol. Environ. Health A 74, 287-295 (2011).
36. Vanoirbeek, J. A., et al. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am. J. Respir. Cell Mol. Biol. 42, 96-104 (2010).
37. Sikic, B. I., Young, D. M., Mimnaugh, E. G., Gram, T. E. Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology. Cancer Res. 38, 787-792 (1978).
38. Chung, M. P., et al. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am. J. Respir. Cell Mol. Biol. 29, 375-380:2003
39. Molyneaux, P. L., Maher, T. M. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 22, 376-381 (2013).
40. Mercer, P. F., Abbott-Banner, K., Adcock, I. M., Knowles, R. G. Translational models of lung disease. Clin. Sci. (Lond) 128, 235-256 (2015).
41. Degryse, A. L., et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 299, L442-L452 (2010).
42. Bauer, Y., et al. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 52, 217-231 (2015).
43. Bivas-Benita, M., Zwier, R., Junginger, H. E., Borchard, G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 61, 214-218 (2005).
44. LeBrasseur, N. K., et al. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 64, 940-948 (2009).
45. Iijima, K., et al. IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure. J. Immunol. 193, 1549-1559 (2014).
46. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798-1806 (2009).
47. Hubner, R. H., et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44, 507-511 514-507 (2008).
48. Hansen, K. D., Irizarry, R. A. Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13, 204-216 (2012).
49. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).